Recruiting

Fabla-diabetesMM

Sponsor:

Emory University

Code:

NCT07474376

Conditions

Diabetes Mellitus, Type 2

Diabetes Mellitus, Type 1

Eligibility Criteria

Sex: All

Age: 65+

Healthy Volunteers: Not accepted

Interventions

Fabla Mobile App

Study Details

Brief summary:

The goal of this clinical trial is to evaluate whether an audio diary mobile application (Fabla-diabetesMM) is feasible to use and may support self-management in older adults with type 1 or 2 diabetes and multimorbidity.

The main questions it aims to answer are:

  • Is it feasible to adapt and implement the Fabla-diabetesMM audio diary mobile app among 30 older adults with diabetes and multimorbidity
  • Does the use of the audio diary mobile app affect self-management outcomes

Conditions

Diabetes Mellitus, Type 2

Diabetes Mellitus, Type 1

Study ID

NCT07474376

Start date

Sep, 2026

Status verified date

Aug, 2026

Completion date

Mar, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 65+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosed type 1 or 2 diabetes and at least one comorbidity (eg, obesity, HIV, heart failure, polycystic ovary syndrome, obstructive sleep apnea, and prediabetes with and without hypertension)
  • Being able to fill in the Redcap surveys, and install and use the audio diary app.

Exclusion Criteria:

•Those who cannot use (e.g., no mobile phone, incompatible system), read, type, speak, or understand English in Redcap or the audio diary mobile app.

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Single-Arm Feasibility Intervention

Participants are older adults (≥65 years) with type 1 or type 2 diabetes and at least one comorbidity. All participants receive the adapted Fabla-diabetesMM audio diary mobile application and complete structured surveys and audio diary entries over 7 days and up to 1-3 months.

Interventions

Fabla Mobile App

Participants will use an adapted audio diary mobile application (Fabla-diabetesMM) designed to collect daily structured and semi-structured audio reflections on health conditions, symptoms, self-management strategies, goal attainment, and feasibility feedback. The app is tailored for older adults, including adjustments to interface, font, navigation, and question wording.

Intervention Components:

  • Daily audio diary entries for 7 days, with optional continued use up to 1 or 3 months
  • Structured survey items integrated into the app (e.g., symptoms, self-regulation, self-efficacy, healthcare use)
  • Semi-structured audio prompts about daily experiences, self-management, and health changes
  • Reminder notifications to encourage diary completion
  • Video instructions on how to use the app

Primary outcome measure

  • Feasibility of the Audio Diary Mobile App [ Time Frame: Day 1-7; Day 7-1 or 3 months ]
  • Expressiveness [ Time Frame: Day 1-7; Day 7-1 or 3 months ]
  • Acceptability, Appropriateness, and Feasibility Measures [ Time Frame: Day 1-7; Day 7-1 or 3 months ]
  • System Usability Scale [ Time Frame: Day 1-7; Day 7-1 or 3 months ]
  • Rates of interest [ Time Frame: Screening ]
  • Rates of eligibility [ Time Frame: Screening ]
  • Rates of completion [ Time Frame: Day 1; Day 1-7; Day 7; Day 7-1 or 3 months; 1 month; 3 months ]
  • Linguistic Inquiry and Word Count (LIWC) analysis of the audio diaries [ Time Frame: Day 1-7; Day 7-1 or 3 months ]

Central Contacts and Locations

Central contacts

Wenhui Zhang, PhD

762-499-0411wenhui.zhang@emory.edu

Locations

Emory Healthcare

Recruiting

Atlanta, Georgia, United States, 30329

Contacts

Wenhui Zhang, PhD

762-499-0411wenhui.zhang@emory.edu

More Information

Sponsor

Emory University

Last update posted

Aug 17, 2026

Last verified

Aug, 2026

Keywords

  • Diabetes self management

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Emory University on 2026-08-17.